Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“For years, we’ve been prescribing both apixaban and rivaroxaban for acute VTE as if they were identical twins.
They’re not.
The COBRRA trial just published in NEJM (Castellucci LA et al., 2026) is the first randomised head-to-head comparison of these two DOACs in acute symptomatic VTE.
And the results are clear.
Here’s what the data shows:
- Clinically Relevant Bleeding: 3.3 percent with apixaban versus 7.1 percent with rivaroxaban
- Major Bleeding: 0.4 percent versus 2.4 percent (RR 0.16 – that is not a small difference)
- Recurrent VTE: 1.1 percent versus 1.0 percent (no meaningful difference)
Same protection. Less bleeding. That’s a win for patients.
This was a pragmatic, open-label, blinded-endpoint trial with 1:1 allocation across acute proximal DVT and PE.
Real-world design. Blinded outcome adjudication. Three months follow-up.
The limitation worth noting: it excluded active cancer, pregnancy, severe renal impairment, and extreme body weight.
So this applies to your standard acute VTE patient, not every patient.
But for that standard patient?
The choice just got easier.
Apixaban appears to be the safer DOAC for acute VTE treatment when bleeding risk matters. And bleeding risk always matters.
Does this change your practice?
Are you already defaulting to apixaban, or does your institution still treat them as equivalent?
Drop your thoughts below.”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause